MPC-6827 is being developed by Myriad from a family of anticancer analogs discovered by Maxim through its proprietary high-throughput screening system, which identifies compounds and molecular targets that induce programmed cell death, or apoptosis.
In preclinical studies, MPC-6827 was notable in its breadth of activity, demonstrating activity that was better than control using current standard-of-care chemotherapy in xenograft models of breast, pancreas, colon, ovary and prostate cancers. The compound targets a novel intracellular target and shows selectivity for breast and colorectal cancer.
“We are very pleased with Myriad’s progress in the MPC-6827 program and look forward to the phase I study results,” stated Larry Stambaugh, Maxim’s chairman and CEO. “In the meantime we are continuing our efforts to advance other anticancer compounds into the clinic.”